Hamilton Medical recalls (Class 1) certain lots of coaxial breathing sets due to a quality issue involving a defective blade in the tube-cutting stage of production that may lead to a crack in the inner blue limb of the circuit.
Johnson & Johnson decides to stop development of nipocalimab in combination with an anti-tumor necrosis factor alpha therapy for rheumatoid arthritis after a mid-stage proof-of-concept study failed to show added benefit.
Hamilton Medical recalls (Class 1) certain lots of coaxial breathing sets due to a quality issue involving a defective blade in the tube-cutting stage of production that may lead to a crack in the inner blue limb of the circuit.
Johnson & Johnson decides to stop development of nipocalimab in combination with an anti-tumor necrosis factor alpha therapy for rheumatoid arthritis after a mid-stage proof-of-concept study failed to show added benefit.
Novocure stops its LUNAR-4 study, a Phase 2 open-label trial testing Tumor Treating Fields together with Merck’s Keytruda (pembrolizumab) in lung cancer (NSCLC) patients after deciding that real-world evidence can instead meet the study’s objectives.
FDA warns Orlando, FL-based Platinum Biologics that it is illegally marketing unapproved new drugs.
